Victoria M. Ettorre, DO, MS
Clinical AssociateAbout
Research
Publications
2025
Long lasting response to the combination of Avutometinib and Defactinib after progression on Binimetinib in a patient with recurrent low grade serous ovarian carcinoma − A case report
Ettorre V, Palmieri L, Ottum S, Greenman M, Santin A. Long lasting response to the combination of Avutometinib and Defactinib after progression on Binimetinib in a patient with recurrent low grade serous ovarian carcinoma − A case report. Gynecologic Oncology Reports 2025, 102011. DOI: 10.1016/j.gore.2025.102011.Peer-Reviewed Original ResearchLow grade serous ovarian cancerA Case ReportMEK inhibitorsAromatase inhibitorsTreatment optionsMultiple lines of chemotherapyBackground treatmentMEK inhibitor binimetinibDose-limiting toxicityLines of chemotherapyLong lasting responsesSerous ovarian cancerStandard treatment optionOral drug combinationsNovel treatment optionsMEK-162CA-125Partial responseDose reductionOvarian cancerPlatinum resistanceKRAS mutationsTargeted therapyDrug combinationsProlonged responseFolate receptor alpha as a successful biomarker in the treatment of low-grade serous ovarian cancer patients using preclinical and clinical models
Ettorre V, Conca B, Demirkiran C, Bellone S, Sethi N, Hartwich T, Niu N, Buza N, Angioli R, Plotti F, Palmieri L, Santin A. Folate receptor alpha as a successful biomarker in the treatment of low-grade serous ovarian cancer patients using preclinical and clinical models. International Journal Of Gynecological Cancer 2025, 36: 102779. PMID: 41411700, DOI: 10.1016/j.ijgc.2025.102779.Peer-Reviewed Original ResearchLGSOC patientsLow-grade serous ovarian cancerSerous ovarian cancer patientsOvarian cancer patientsPatient-derived xenograft modelsSerous ovarian cancerMirvetuximab soravtansineStandard treatment modalityOvarian cancerFOLR1 expressionCancer patientsXenograft modelTreatment modalitiesRecurrent low-grade serous ovarian cancersResistant to standard treatment modalitiesClinical activitySerous ovarian cancer casesEpithelial ovarian cancer subtypesSevere combined immunodeficient miceProlonged partial responseOvarian cancer casesMEK inhibitor treatmentOvarian cancer subtypesMonths of treatmentResistance to chemotherapyA PHASE II EVALUATION OF THE EFFICACY AND SAFETY OF SACITUZUMAB GOVITECAN IN PATIENTS WITH RECURRENT UTERINE CANCER
Santin A, Roque D, Siegel E, Ettorre V, Greenman M, Mcnamara B, Papatla K, Kailasam A, Azodi M, Buza N, Clark M, Hui P, Altwerger G, Dottino P, Ratner E, Bellone S. A PHASE II EVALUATION OF THE EFFICACY AND SAFETY OF SACITUZUMAB GOVITECAN IN PATIENTS WITH RECURRENT UTERINE CANCER. International Journal Of Gynecological Cancer 2025, 35: 102143. DOI: 10.1016/j.ijgc.2025.102143.Peer-Reviewed Original ResearchSuccessful Sequential Use of the Antibody-Drug Conjugate Trastuzumab Deruxtecan After Progression on Sacituzumab Govitecan in a Recurrent Treatment-Resistant Ovarian Cancer Patient: A Case Report
Ettorre V, Greenman M, Palmieri L, Demirkiran C, Santin A. Successful Sequential Use of the Antibody-Drug Conjugate Trastuzumab Deruxtecan After Progression on Sacituzumab Govitecan in a Recurrent Treatment-Resistant Ovarian Cancer Patient: A Case Report. Cureus 2025, 17: e94784. PMID: 41257122, PMCID: PMC12620085, DOI: 10.7759/cureus.94784.Peer-Reviewed Original ResearchHigh-grade serous ovarian cancerAntibody-drug conjugate trastuzumab deruxtecanAntibody-drug conjugatesOvarian cancer patientsTrastuzumab deruxtecanSacituzumab govitecanPlatinum resistanceTreatment optionsCancer patientsHigh-grade serous ovarian cancer patientsRecurrent ovarian cancer patientsDose-limiting toxicityAbdominal tumor massSerous ovarian cancerLiver metastatic lesionsEffective treatment optionNovel treatment optionsSequential useCA-125Metastatic lesionsDose reductionClinical responseOvarian cancerTumor massAnti-HER2Immunohistochemistry, next generation sequencing (NGS), and whole exome sequencing concordance in HER2 testing in uterine serous carcinoma: a retrospective analysis
Ettorre V, Bellone S, Buza N, Hui P, Hartwich T, Demirkiran C, Greenman M, Sethi N, Palmieri L, Santin A. Immunohistochemistry, next generation sequencing (NGS), and whole exome sequencing concordance in HER2 testing in uterine serous carcinoma: a retrospective analysis. Gynecologic Oncology 2025, 202: 131-136. PMID: 41092695, DOI: 10.1016/j.ygyno.2025.09.017.Peer-Reviewed Original ResearchConceptsUterine serous carcinomaWhole-exome sequencingFluorescent-in-situ hybridizationNext generation sequencingHER2-positiveSerous carcinomaImmunohistochemistry stainingCorrelation of HER2HER2-Targeted TherapyHER2-targeted treatmentTissue blocksGeneration sequencingTreatment-eligible patientsComprehensive whole-exome sequencingEvaluation of patientsNext generation sequencing dataNext generation sequencing platformsFluorescence in situ hybridizationUSC patientsHER2 testingERBB2 amplificationHER2 expressionTherapeutic optionsRetrospective analysisHER2Preclinical Efficacy of the Estrogen Receptor Degrader Fulvestrant in Combination with RAF/MEK Clamp Avutometinib and FAK Inhibitor in a Low-Grade Serous Ovarian Cancer Animal Model with Acquired Resistance to Chemotherapy and Aromatase Inhibitor
Demirkiran C, Bellone S, Ettorre V, Mansolf M, Hartwich T, McNamara B, Greenman M, Yang-Hartwich Y, Ratner E, Santin N, Sethi N, Palmieri L, Coma S, Pachter J, Ottum S, Santin A. Preclinical Efficacy of the Estrogen Receptor Degrader Fulvestrant in Combination with RAF/MEK Clamp Avutometinib and FAK Inhibitor in a Low-Grade Serous Ovarian Cancer Animal Model with Acquired Resistance to Chemotherapy and Aromatase Inhibitor. International Journal Of Molecular Sciences 2025, 26: 8924. PMID: 41009492, PMCID: PMC12469703, DOI: 10.3390/ijms26188924.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic Combined Chemotherapy ProtocolsAromatase InhibitorsCell Line, TumorDisease Models, AnimalDrug Resistance, NeoplasmFemaleFocal Adhesion Kinase 1FulvestrantHumansMiceMice, SCIDOvarian NeoplasmsProtein Kinase InhibitorsReceptors, EstrogenXenograft Model Antitumor AssaysConceptsPatient-derived tumor xenograftTriple combinationFocal adhesion kinasePreclinical efficacyAromatase inhibitorsClinical evaluationEstrogen receptor (ER)-positiveAcquired resistance to chemotherapyOvarian cancer animal modelEstrogen receptor degrader fulvestrantPatients wild-typeVS-4718Cancer animal modelTumor growth inhibitionLimited treatment optionsResistance to chemotherapyP-ERK levelsFocal adhesion kinase inhibitorMedian survivalRare tumorOvarian carcinomaRecurrence rateTumor xenograftsTreatment optionsFulvestrantEffective preclinical activity of datopotamab deruxtecan (Dato-DXd), an ADC targeting trophoblast cell-surface antigen 2 (TROP2), against primary cervical carcinoma cell lines and xenografts
Ettorre V, Demirkiran C, Bellone S, Hartwich T, Greenman M, McNamara B, Sethi N, Palmieri L, Santin A. Effective preclinical activity of datopotamab deruxtecan (Dato-DXd), an ADC targeting trophoblast cell-surface antigen 2 (TROP2), against primary cervical carcinoma cell lines and xenografts. Gynecologic Oncology 2025, 201: 195-202. PMID: 40907200, DOI: 10.1016/j.ygyno.2025.08.027.Peer-Reviewed Original ResearchTrophoblast cell surface antigen 2Primary cervical cancer cell linesAntibody-directed cellular cytotoxicityCervical cancer cell linesIn vivo anti-tumor activityAntibody-drug conjugatesCancer cell linesTumor cell deathTumor cellsNon-expressing cell linesCell linesTrophoblast cell surface antigen 2 expressionPreclinical pharmacologyClinical evaluationExpression of trophoblast cell surface antigen 2Cervical cancer mouse modelMedian overall survivalNegative tumor cellsCancer mouse modelCervical cancer patientsTumor growth suppressionCervical carcinoma cell linesCell deathCarcinoma cell linesMarkers of apoptosisPreclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas
Santin N, Sethi N, Bellone S, Demirkiran C, Ettorre V, Greenman M, McNamara B, Buza N, Hartwich T, Palmieri L, Lorusso D, Santin A. Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas. Cancer Research Communications 2025, 5: 1611-1620. PMID: 40862536, PMCID: PMC12423748, DOI: 10.1158/2767-9764.crc-25-0251.Peer-Reviewed Original ResearchConceptsEndometrial cancer cell linesTrophoblast antigen 2Antibody-dependent cell cytotoxicityAntibody-drug conjugatesEndometrial cancer xenograftsCancer cell linesEndometrial cancerPreclinical activityBystander killingCancer xenograftsCell linesPreclinical evidenceIn vivo activityCell cytotoxicityTargeted treatmentPrimary tumor cell linesBiomarker-targeted therapiesNovel antibody-drug conjugatesControl ADCRecurrent endometrial cancerChromium release assayFlow cytometry-based assayTumor growth inhibitionIn vivoCytometry-based assayPreclinical efficacy of the estrogen receptor degrader fulvestrant in combination with RAF/MEK clamp avutometinib and FAK inhibitor in low-grade serous ovarian cancer with acquired resistance to chemotherapy and aromatase Inhibitor
Demirkiran C, Bellone S, Ettorre V, Hartwich T, Greenman M, McNamara B, Yang Y, Ratner E, Schwartz P, Coma S, Pachter J, Santin A. Preclinical efficacy of the estrogen receptor degrader fulvestrant in combination with RAF/MEK clamp avutometinib and FAK inhibitor in low-grade serous ovarian cancer with acquired resistance to chemotherapy and aromatase Inhibitor. Gynecologic Oncology 2025, 200: 315. DOI: 10.1016/j.ygyno.2025.04.448.Peer-Reviewed Original ResearchDatopotamab deruxtecan, a TROP2-directed antibody-drug conjugate, demonstrates antitumor activity in uterine serous carcinoma
Greenman M, Demirkiran C, Bellone S, Ettorre V, Hartwich T, McNamara B, Yang Y, Altwerger G, Ratner E, Clark M, Papatla K, Azodi M, Dottino P, Schwartz P, Santin A. Datopotamab deruxtecan, a TROP2-directed antibody-drug conjugate, demonstrates antitumor activity in uterine serous carcinoma. Gynecologic Oncology 2025, 200: 204. DOI: 10.1016/j.ygyno.2025.04.263.Peer-Reviewed Original Research